Barry J. Maron, MD Hypertrophic Cardiomyopathy Institute Tufts Medical Center Boston, MA. Disclosures: Medtronic (Grantee) GeneDx (Consultant)
|
|
- Mervyn Jackson
- 5 years ago
- Views:
Transcription
1 How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality Shaped by 50 Years of Clinical Research and Practice Barry J. Maron, MD Hypertrophic Cardiomyopathy Institute Tufts Medical Center Boston, MA Disclosures: Medtronic (Grantee) GeneDx (Consultant)
2 First Principle: HCM is a disease compatible with normal longevity without disability or need for intervention
3 % of Patients Major Adverse Disease Pathways in HCM 60 56% % % 8% 0 Major Treatment End-Point Pathways
4 Benign/Stable (normal longevity) Profiles in Prognosis for HCM Sudden Death Progressive Heart Failure End- Stage AF & Stroke
5 U.S./Canada: ACC/AHA: prevention Cardiac arrest/sustained VT 1 prevention Family history HCM-SD Unexplained syncope Multiple-repetitive NSVT (Holter) Abnormal exercise BP response LGE 15% of LV mass Massive LVH 30 mm Rare subgroups/potential arbitrators End-stage (EF < 50%) LV apical aneurysm Marked LV outflow obstruction (rest) Modifiable Intense competitive sports CAD LGE 15% of LV mass Age 60y Alcohol septal ablation (?) Highest Intermediate Lowest ICD
6 % Patients With SCD Relation Between LV Thickness & SCD in 482 HCM Patients < Max. LV Wall Thickness (mm)
7 Echo CMR A B RV VS LV * * * RV VS LV
8 U.S./Canada: ACC/AHA prevention Cardiac arrest/sustained VT 1 prevention Family history HCM-SD Unexplained syncope Multiple-repetitive NSVT (Holter) Abnormal exercise BP response LGE 15% of LV mass Massive LVH 30 mm Rare subgroups/potential arbitrators End-stage (EF < 50%) LV apical aneurysm Marked LV outflow obstruction (rest) Modifiable Intense competitive sports CAD LGE 15% of LV mass Age 60y Alcohol septal ablation (?) Highest Intermediate Lowest ICD
9 % of HCM Cohort Outcome of HCM Patients First Evaluated 60 Years % Aging is Good in HCM % 12% 0.2%/y 0 Maron BJ et. al. Circ 2013; 127: 585 Alive Non- Cardiac Death Non-HCM Cardiac Death 2% 1% 1% Embolic Stroke Heart Failure HCM Death SCD
10 Risk Stratification for Sudden Death in HCM Family history of sudden death Extreme LVH Nonsustained VT Unexplained syncope Abnormal BP response to Ex High Intermediate Moderate No risk factors Low Risk 0.5%/year
11 U.S./ Canada (ACC/AHA) prevention Cardiac arrest/sustained VT 1 prevention Family history HCM-SD Unexplained syncope Multiple-repetitive NSVT (Holter) Abnormal exercise BP response LGE 15% of LV mass Massive LVH 30 mm Rare subgroups/potential arbitrators End-stage (EF < 50%) LV apical aneurysm Marked LV outflow obstruction (rest) Modifiable Intense competitive sports CAD LGE 15% of LV mass Age 60y Alcohol septal ablation (?) Highest Intermediate Lowest ICD
12 A P VS D B P D C VS P Figure 1. D LA D E F * * * * * *
13 HCM with Apical Aneurysm and Scar
14 Survival free from HCM related mortality and adverse events HCM Related Death or Adverse Clinical Events in 93 Patients with LV Apical Aneurysms %/year 0.6 Log-rank test p< %/year 0.2 HCM patients without LV apical aneurysms HCM patients with LV apical aneurysm Years from First Evaluation
15 A B C VS LV VS RV Prevalence of LGE = 55-70% D E F LA LA
16 Survival Extent of LGE vs. Sudden Death Risk in HCM LGE LGE L G E LGE (-) LGE < 10% LGE 10-20% LGE > 20% Follow-up (years) Chan RH et. al. Circ 2014; 130(6):
17 2 prevention Cardiac arrest/sustained VT 1 prevention Family history HCM-SD Unexplained syncope Multiple-repetitive NSVT (Holter) Abnormal exercise BP response LGE 15% of LV mass Massive LVH 30 mm Rare subgroups/potential arbitrators End-stage (EF < 50%) LV apical aneurysm Marked LV outflow obstruction (rest) Modifiable Intense competitive sports CAD LGE 15% of LV mass Age 60y Alcohol septal ablation (?) Highest Intermediate Lowest ICD
18 Prevention of Sudden Death in HCM
19 ICD Performance in HCM 506 Follow-up = 3.7 ± 3 years 103 Appropriate Shocks (20%) VT/VF 5.5%/y ICD discharge rate 11%/y 4%/y 2º prevention 1º prevention Maron BJ et. al. JAMA 2007; 298:
20 Rate of Appropriate Interventions per 100 person-yr Appropriate Shocks (35%) Overall p= No. of Risk Factors for Primary Prevention
21 Primary Prevention Decision Tree: ICD In HCM Risk Factors High risk? Some risk Cardiologist TRANSPARENCY / FULL DISCLOSURE / INFORMED CONSENT Patient Autonomy
22 NEW PARADIGM IN HYPERTROPHIC CARDIOMYOPATHY
23 Evidence for Decreased HCM Mortality: 2000 Patients Presenting years Old Tufts Medical Center What is Possible..and Role of HCM Centers
24 % Death Per Year Maron BJ et. al. JACC in press 1.4 Pre-ICD era 1.5%/y %/y 86 ICD interventions General Population "Historic Mortality"
25 % Death Per Year %/y 0.8%/y General Population "Historic Mortality"
26 % Death Per Year %/y 0.8%/y 45 Transplants 0.0 General Population "Historic Mortality"
27 % Death Per Year %/y %/y General Population "Historic Mortality"
28 % Death Per Year %/y 0.6%/y General Population "Historic Mortality" 30 OHCA (w/ hypothermia)
29 % Death Per Year Current Mortality lives saved 0.8%/y p = %/y
30 % Death Per Year %/y Advanced Heart Failure (n = 21) SCD (n = 15) Stroke (n=1) Current Mortality 2014
31 % Death Per Year %/y Advanced Heart Failure (n = 21) SCD (n = 15) Stroke (n=1) Current Mortality SCDs but 5 declined ICD 7 pre-icd era
32 HCM-Related Mortality (n = 474) (n = 1000) (n = 428) Age in Years Initial Evaluation
33 Sudden Death Advanced HF
34 Paradigm Change in Causes of Death: Advanced Heart Failure w/o Obstruction (transplant/transplant candidates) (60%) All HCM Patients 3% Current Causes of HCM Mortality (2015)
35 Survival Surgical Myectomy: Quality of Life/Survival Reversal Form of HF % Isolated Myectomy Nonoperated obstructive Expected ---US population P< % Years Post-op Ommen S et. al. JACC 2006
36 Major Surgical Myectomy Centers (North America) Center No. Myectomy Mort. Mayo % Cleveland % Tufts % Toronto % NYU % %
37 WHO SHOULD DO IT? (Operative Mortality) Community Hospitals 8% HCM Centers 0.4%
38 Relation of Progressive Heart Failure to Outflow Obstruction Non- Obstructive Provocable Obstruction Rest Obstruction No. Patients Proportion of patients who developed NYHA class III/IV 10% 90% 20% 80% 38% 62% Rate of Progression to NYHA Class III/IV, (%/y) 1.6%/y 3.2%/y 7.4%/y
39 ITS PROBABLY BETTER TO BE NONOBSTRUCTIVE..UNLESS YOU GET REALLY SICK
40 % HCM Mortality %/y Early HCM Referral Cohorts HCM Cohorts: Prior to utilization of current treatment strategies/ interventions 1 1.5%/y ICD intervention Heart transplant/myectomy OHCA/defibrillation/hypothermia %/y Present HCM Cohort: Contemporary treatment 0.8%/y 0 HCM-Related Mortality General U.S. Population
41 Most HCM Patients Do Not Die of HCM 75% of HCM Patients Die of Other, Most Commonly Non-Cardiac, Conditions Most HCM-Related Deaths occur in Younger Patientsp
42 Benign/Stable (normal longevity) Profiles in Prognosis for HCM Sudden Death Progressive Heart Failure (obstructive) Advanced Heart Failure & End Stage (nonobstructive) AF & Stroke ICD Drugs Septal Myectomy (Alcohol Ablation) Transplant Drugs Anticoagulants Ablation
43 New HCM Paradigms: 1. Contemporary Treatable Disease Compatible w/ Low Mortality & Extended/Normal Longevity 2. Rx Interventions Are Available That Change Clinical Course of the Disease
44
45
46 % HCM Patients Survival to Advanced Age in HC % 15 14% % 2% 70 years 75 years 80 years 90 years Survival Age
47 The ESC-HCM prediction formula for SD is as follows: Probability SCD at 5 years = exp (Prognostic index) ; where Prognostic index = [ x maximal LV wall thickness (mm)] [ x LV maximal wall thickness 2 (mm 2 )] + [ x left atrial diameter (mm)] + [ x maximal (rest/valsalva) LV outflow tract gradient (mm Hg)] + [ x family history SCD] + [ x NSVT] + [ x unexplained syncope] [ x age at clinical evaluation (years)].
48 HCM is Unpredictable
49 No. Patients 16 ICD in HCM: Time to First Shock >90 Duration (months) Maron BJ et. al. JAMA 2007;298:
50 161 saved
51 At this time we are aware of no method of management that can specifically and favorably influence the course of a patient with idiopathic ventricular hypertrophy. Eugene Braunwald Edwin C. Brockenbrough Andrew G. Morrow Circulation, Volume XXVI, August 1962
52 LGE as the Only Risk Factor A B VS LV C
53 Assessment of ESC Sudden Death Risk Score (n = 1649) % Patients With/Without ICD Intervention/Sudden Death 60% 63% 26% 9% <4% 4-6% >6% <4% 4-6% >6% Risk/5y Risk/5y Appropriate ICD Intervention ESC Risk Score No Appropriate ICD Intervention <4% 4-6% >6% Risk/5y Sudden Death
54
55 % of Patients 60 56% % % 1% No. of End-Point Pathways
56 Adverse Pathway Pathway End-Point 476 Outcome 21 Death HCM 52 Death non-hcm 403 Survived AF Death HCM Death non-hcm Survived Death HCM Death non-hcm Survived
57 2 Adverse Pathways 8 Death - HCM Death - non-hcm 109 Survived 10 Death - HCM 204 (9%) HF + SD 38 4 Death - non-hcm 24 Survived 2 Death - HCM 12 1 Death - non-hcm 9 Survived
58 2 y HCM Diagnosis (SD in 2 brothers) #1 #2 #3 #4 #5/6 ICD interventions #7 #8 # Asymptomatic ICD implant Heart failure Myectomy
59 3 Adverse Pathways HCM-related 6 27 (1%) 7 Died 1 Non- HCM-related 20 Survived NYHA I/II = 16 III = 4
60
61
62 Proportion of Patients Surviving Time (years) %/year 1.2 %/year 2.4 %/year p= Pathway = 0 Pathway = 1 Pathway = 2 Pathway =
63 Patients with LVAA (n=28) Alive/ Clinically Stable (n = 16)* Adverse Events (n = 12) non-fatal embolic stroke (1) Sudden Death (2)* Aborted Cardiac Arrest (2) Progressive Heart Failure/ Death (5) Appropriate ICD Discharge (3)* non-fatal embolic stroke (1) Cardiovascular Event Rate = 11%/year
64 ICD in HCM for Children / Adolescents 224 No. Patients 43 Appropriate ICD Discharge (19%) Follow-up= 4.3 ± 3.3 yr 4.4% / yr Initial shock 9-23 y (mean= 17 y) 13%/yr 3%/yr 2 prevention 1 prevention Maron BJ et. al. JACC 2013; 61:
65 No. Patients 16 ICD in HCM - II: Time to First Shock >90 Duration (months) Maron BJ et. al. JAMA 2007;298:
66 HCM is Unpredictable
67 Profiles in Prognosis for HCM Sudden Death Risk Symptom Progression End- Stage AF
68 CARDIA N=4,111;23-35 y 0.17% Rural Minnesota N=15,137;16-87 y 0.19% Japan N=3,354;20-77 y 0.17% Amer Indians N=3,501;51-77 y 0.2% General Population 1: ,000 people in U.S. China N=8,080;18-74 y 0.16% Tanzania N=6,680;22-91 y 0.2% AT RISK: 50, ,000?
69 A B C VS LV VS RV Prevalence of LGE = 55-70% D E F LA LA
70 Genetic Testing Prognosis To identify HCM (w/ LVH) HCM (w/o LVH) Genotype + Phenotype - Follow-up
71 Evidence for Decreased HCM Mortality: 2000 Patients Presenting in Mid-Life (30-59y) MHIF/Tufts What is Possible..
72 Unexplained LVH Sarcomeric Protein Mutations Non-Sarcomeric Mutations ~ 11 Genes--- or more? > 1500 mutations AMP-Kinase (PRKAG2) Lamp2 (Danon) Storage Diseases Fabry Disease
73 HCM Is A Global Disease 50 countries.all continents
74 N Engl J Med 1980;303:322.
75 Dr. Michele Mirowski
76 Sudden Death in Young Athletes HCM (36%) Dilated CM (2%) Coronary Anomalies (17%) Maron, BJ et. al. Circulation :
77 K.K. 23 Years with ICD and HCM 5 y 9 y 8 y BD: 2/19/ Brother SD (HCM) ICD implant Shock Polymorphic VT (203/min) VF x2 shocks (2 mo. apart) AF* (cardioverted) Amio 200 mg Xeralto * preceded by asymptomatic AF on ICD (3 weeks)
78 25-Year Contemporary Initiatives in Hypertrophic Cardiomyopathy Genetic (molecular) Single sarcomere mutation hypothesis Clinicians Lives Saved Improved Quality of Life 0 Thousands 0 Many thousands
79 Septal Scarring Post-ablation Post-myectomy Septal Scar VS=30% LV 10% No Scar Valeti et. al. JACC 2007;49:350
80 LGE as the Only Risk Factor A B VS LV C Maron BJ et. al. AJC 2008; 101(4):544-7
81 HCM ICD Registry 29 (6%) Deaths 14 No HCM HCM HCM- Arrhythmias (nl EF) 1 Cancer, sepsis, renal diseases, suicide, CAD, accidents 14 End-stage Embolic stroke ICD Malfunction Maron, BJ et. al. JAMA 2007;298:405
82 Cumulative survival in NYHA Class I-II (%) Impact of Outflow Obstruction (> 30mmHg) on Progression to Severe Heart Failure - Related Symptoms and Death in 1101 HCM Patients Nonobstructive p= RR= 4.4 Obstructive Years from First Gradient Measurement Maron,MS NEJM 2003:348:295
83 Cardiovascular Societies & HCM Consensus Panels for Myectomy vs. Alcohol Ablation ACC 2003 ESC 2003 ACC 2011 AHA 2011 Myectomy Myectomy Myectomy Myectomy
84
85 HCM : The Tip Of The Iceberg Identified? Unidentified
86 No. Affected / Million The Uncommon Diseases
87 CONTEMPORARY HCM MORTALITY BY AGE: MHIF/Tufts 2015 <29 y y >60 y Total No. Patients HCM Mortality %/y 0.5%/y 0.6%/y 0.5%/y
88 Clinical Course in 70 HCM Patients with LV Apical Aneurysms 70 HCM patients with LV Apical Aneurysms 41 Alive without Events 9 Apical thrombus identified without thromboembolic history 11 Deaths HCM related death/event rate= 8.1% / year 18 Alive with HCM Events 5 HF Death 2 SCD 4 1 Thromboembolic event 6 years prior to death ICD OOHCA interventions 2 Transplant listing 2 Transplant 3 Noncardiac Thromboembolic event
89 Operative Mortality Associated with Septal Myectomy* at North American Hypertrophic Cardiomyopathy Centers, Operative Deaths** Institution No. Myectomies Age (years) % Male No. % Mayo Clinic (Rochester, MN) Cleveland Clinic 1470 Δ Tufts Medical Center (Boston) Toronto General Mount Sinai-St. Luke s (NYC) ± Totals 3, Symbols: * does not include myectomy associated with valve replacement, coronary artery bypass grafting or resection of a subaortic membrane ** within 30 days of the myectomy includes 2 patients with prior alcohol septal ablation; with these 2 patients considered non-pure myectomies, the Mayo mortality rate would be only 0.15% newest myectomy center with operations performed over only 11 years with first procedure in 2004, while data for the other centers encompasses 15 years Δ includes 19% of patients with mitral valve repair Abbreviations: MN = Minnesota; NYC = New York City
90 HCM is Unpredictable
91
92 (<1%) (15%) (7%) (<1%) (7%) (<1%) (<1%) (15%) (<1%) (<1%)
93
94
95 % HCM Mortality %/y Early HCM Referral Cohorts HCM Cohorts: Prior to utilization of current treatment strategies/ interventions 1 1.5%/y ICD intervention Heart transplant/surgical myectomy RCA/defibrillation/hypothermia %/y Present HCM Cohorts: Contemporary treatment 0.8%/y 0 HCM-Related Mortality General U.S. Population
96 2 prevention Cardiac arrest/sustained VT 1 prevention Family history HCM-SD Unexplained syncope Multiple-repetitive NSVT (Holter) Abnormal exercise BP response LGE 15% of LV mass Massive LVH 30 mm Rare subgroups/potential arbitrators End-stage (EF < 50%) LV apical aneurysm Marked LV outflow obstruction (rest) Modifiable Intense competitive sports CAD LGE 15% of LV mass Age 60y Alcohol septal ablation (?) Highest Intermediate Lowest ICD
97 Annual Mortality (%/year) %/y 1 0.8%/y 0.8%/y %/y 0.5%/y 0 86 ICD Interventions 45 Heart Transplants 30 RCA (+ hypothermia) Current Mortality General Population
98 Benign/Stable (normal longevity) Profiles in Prognosis for HCM Sudden Death Progressive Heart Failure (obstructive) Advanced Heart Failure & End Stage (nonobstructive) AF & Stroke ICD Drugs Septal Myectomy (Alcohol Ablation) Transplant Drugs Anticoagulants RF Ablation
Profiles in Prognosis for HCM
Japan N=3,354;20-77 y 0.17% CARDIA N=4,111; 23-35 y 0.17% Rural Minnesota N=15,137; 16-87 y 0.19% Amer Indians N=3,501;51-77 y 0.2% General Population 1:500 China N=8,080; 18-74 y 0.16% 600,000 people
More informationHCM: The Tip Of The Iceberg. HCM Is A Global Disease. Unidentified. 50 countries.all continents. Rural Minnesota N=15,137;16-87 y 0.
HCM Is A Global Disease 5 countries.all continents CARDIA N=4,111;23-35 y.17% Rural Minnesota N=15,137;16-87 y.19% Japan N=3,354;2-77 y.17% Amer Indians N=3,51;51-77 y.2% General Population 1:5 6, people
More informationHypertrophic Cardiomyopathy: basics and management
Hypertrophic Cardiomyopathy: basics and management Bette Kim, MD Program Director, Cardiomyopathy Program Director, Roosevelt Hospital Echocardiography Lab Assistant Professor of Clinical Medicine Mount
More informationManaging Hypertrophic Cardiomyopathy with Imaging. Gisela C. Mueller University of Michigan Department of Radiology
Managing Hypertrophic Cardiomyopathy with Imaging Gisela C. Mueller University of Michigan Department of Radiology Disclosures Gadolinium contrast material for cardiac MRI Acronyms Afib CAD Atrial fibrillation
More informationTreatment of Hypertrophic Cardiomyopathy in Bruce B. Reid, MD
Treatment of Hypertrophic Cardiomyopathy in 2017 Bruce B. Reid, MD Disclosures I have no conflicts of interest to disclose I will not be discussing any off label medications and/or devices Objectives 1)
More informationHYPERTROPHIC CARDIOMYOPATHY RISK STRATIFICATION WHAT IS NEW?
HYPERTROPHIC CARDIOMYOPATHY RISK STRATIFICATION WHAT IS NEW? Division of Inherited Cardiac Diseases Heart Center for the Young and Athletes A Dpt of Cardiology University of Athens LANCET 2013 ESC HCM
More informationWhat s new in Hypertrophic Cardiomyopathy?
What s new in Hypertrophic Cardiomyopathy? Dr Andris Ellims HCM Clinic @ The Alfred Hypertrophic Cardiomyopathy = otherwise unexplained LV hypertrophy* 1 in 500 prevalence most common inherited cardiovascular
More informationThe Management of Hypertrophic Cardiomyopathy
The Management of Hypertrophic Cardiomyopathy Evidence and Uncertainties Banff 2013 3058464-0 Management of HCM Key Elements Screen 1 relatives for HCM Serial Echo Genetic testing Assess risk for and prevent
More informationThe 2014 Mayo Approach to the Management of HCM and Non-Compaction
The 2014 Mayo Approach to the Management of HCM and Non-Compaction R A Nishimura MD MACC MACP Judd and Mary Morris Leighton Professor Mayo Clinic No disclosures or conflict of interest CP1288794-1 Let
More informationSteel vs Alcohol. Or Neither. Management of Hypertrophic Cardiomyopathy. Josh Doll, MD January 24, 2015
Steel vs Alcohol Or Neither Management of Hypertrophic Cardiomyopathy Josh Doll, MD January 24, 2015 47yo Male, Mr. L Severe progressive dyspnea on exertion and weight gain Previous avid Cross-Fit participant
More informationHYPERTROPHIC CARDIOMYOPATHY: Severe Heart Failure. Paolo Spirito, Genoa, Italy
HYPERTROPHIC CARDIOMYOPATHY: Severe Heart Failure Paolo Spirito, Genoa, Italy Clinical Substrates for Heart Failure Symptoms in HCM Diastolic dysfunction Atrial fibrillation LV outflow obstruction Evolution
More informationThe Management of HOCM: What are the Surgical Options
The Management of HOCM: What are the Surgical Options Konstadinos A Plestis, MD System Chief of Cardiac Thoracic and Vascular Surgery Main Line Health Care System Professor Sidney Kimmel Medical College
More informationCardiac Issues in the Adolescent Athlete. Sean Levchuck, M.D. St. Francis Hospital- The Heart Center
Cardiac Issues in the Adolescent Athlete Sean Levchuck, M.D. St. Francis Hospital- The Heart Center Sudden Cardiac Death Incidence is.6-6.2 % per 100,000 children in the US 20-25 % of the deaths occur
More informationSudden Cardiac Death What an electrophysiologist thinks a cardiologist should know
Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden
More informationHypertrophic Cardiomyopathy: Patient Management in 2018
Hypertrophic Cardiomyopathy: Patient Management in 2018 Mackram F. Eleid, MD Giornate Cardiologeche Torinesi October 26, 2018 2018 MFMER slide-1 Disclosures No relevant financial relationships to disclose
More informationSCD incidence in HCM
Great Debate Risk Stratification Strategies for Reliable Identification of High Risk Patients 2014 ESC Guidelines SCD incidence in HCM Ra8onale for a new approach How to iden8fy the minority of Pts at
More informationHOCM: Alcohol ablation or LVOT Surgery: When and what?
HOCM: Alcohol ablation or LVOT Surgery: When and what? Paul R Vogt/ Pascal A. Berdat Cardiovascular Center Zurich Clinic Im Park Zurich SKG/SGHC Annual Meeting, Zurich, 10.-12.6.15 ASA/Myectomy: Common
More informationHypertrophic Cardiomyopathy: beyond gradient and wall thickness
Hypertrophic Cardiomyopathy: beyond gradient and wall thickness Michael H. Picard, M.D. Massachusetts General Hospital Harvard Medical School no disclosures special thanks to A. Baggish 1 Hypertrophic
More informationRest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome
Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome G. Deswarte, AS. Polge, N. Lamblin, A. Millaire, M. Richardson, C. Bauters,
More informationCardiomyopathies. Andre Keren, MD
Cardiomyopathies Andre Keren, MD Cardiomyopathies Heart muscle disease of unknown etiology Elliott P et al. Eur Heart J 2008;29:270-276 Definition of Cardiomyopathies Elliott P et al. Eur Heart J 2008;29:270-276
More informationSudden cardiac death: Primary and secondary prevention
Sudden cardiac death: Primary and secondary prevention By Kai Chi Chan Penultimate Year Medical Student St George s University of London at UNic Sheba Medical Centre Definition Sudden cardiac arrest (SCA)
More informationCases in Stress Echo DISCLOSURE
Cases in Stress Echo Susan Wilansky, MD, FRCP(C), FACC, FASE Mayo Clinic, AZ DISCLOSURE Relevant Financial Relationship(s) None Off Label Usage None 1 Exercise Testing in Patients with HCM (Class IIa)
More informationTachycardia Devices Indications and Basic Trouble Shooting
Tachycardia Devices Indications and Basic Trouble Shooting Peter A. Brady, MD., FRCP Cardiology Review Course London, March 6 th, 2014 2011 MFMER 3134946-1 Tachycardia Devices ICD Indications Primary and
More informationHCM GUIDELINES ESC 2014 HYPERTROPHIC CARDIOMYOPATHY ASYMPTOMATIC PATIENT
HCM GUIDELINES ESC 2014 HYPERTROPHIC CARDIOMYOPATHY ASYMPTOMATIC PATIENT Division of Inherited Cardiac Diseases Heart Center for the Young and Athletes A Dpt of Cardiology University of Athens ASYMPTOMATIC
More informationCardiomyopathy in Fabry s disease
Cardiomyopathy in Fabry s disease Herzinsuffizienzlunch Basel, 11.09.2018 Christiane Gruner Kardiologie, UniversitätsSpital Zürich Content Background / epidemiology Differential diagnosis Clinical presentations
More information2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy Developed in Collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography,
More informationUtility of Echocardiography
Hypertrophic Cardiomyopathy and Beyond- Echo Hawaii 2018 Lawrence Rudski MD FRCPC FACC FASE Professor of Medicine Director, Division of Cardiology and Azrieli Heart Center Jewish General Hospital, McGill
More informationGenotype Positive/ Phenotype Negative: Is It a Disease?
Genotype Positive/ Phenotype Negative: Is It a Disease? Michelle Michels MD, PhD Center of Inherited Cardiovascular Diseases Erasmus MC, Rotterdam, the Netherlands No disclosures What is phenotype negative
More informationSudden Death (SD) and hypertrophic cardiomyopathy (HCM) Attempt of risk stratification
Sudden Death (SD) and hypertrophic cardiomyopathy (HCM) Attempt of risk stratification 84th Annual Scientific Meeting of the Aerospace Medical Association May 12-16, 2013 Sheraton Chicago Hotel & Towers,
More informationSilvia G Priori MD PhD
The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics
More informationI have nothing to disclose. Research support from: Cardiac Risk in The Young
I have nothing to disclose. Research support from: Cardiac Risk in The Young Pre-participation screening of Young Athletes: Current Perspective Professor Sanjay Sharma Disclosures: None SCD in Young Athletes
More informationESC Guidelines on Hypertrophic Cardiomyopathy
2014 version ES Guidelines on Hypertrophic ardiomyopathy Pr Michel KOMAJDA Dept of ardiology HU PTE SALPETRERE University Pierre et Marie urie PARS FRANE European Heart Journal (2014):doi:10.1093/eurheartj/ehu284
More informationAnaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO)
Anaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO) Dr. Siân Jaggar Consultant Anaesthetist Royal Brompton Hospital London UK Congenital Cardiac Services
More informationSurgical Myectomy for HOCM
Surgical Myectomy for HOCM Volkmar Falk Deutsches Herzzentrum Berlin Different Pathology of HOCM Impact on surgical strategy Said SM Expert Rev Cardiovasc Ther 2013 Different Pathology of HOCM Impact on
More informationLeft ventricular non-compaction: the New Cardiomyopathy on the Block
Left ventricular non-compaction: the New Cardiomyopathy on the Block Aamir Jeewa MB BCh, FAAP, FRCPC Section Head, Cardiomyopathy & Heart Function Program The Hospital for Sick Children Assistant Professor
More informationCitation for published version (APA): Christiaans, I. (2010). Hypertrophic cardiomyopathy: towards an optimal strategy
UvA-DARE (Digital Academic Repository) Hypertrophic cardiomyopathy: towards an optimal strategy Christiaans, I. Link to publication Citation for published version (APA): Christiaans, I. (2010). Hypertrophic
More informationCardiac Resynchronization Therapy. Michelle Khoo, MD
Cardiac Resynchronization Therapy Michelle Khoo, MD 10.7.08 HuiKuri HV NEJM 2001 Sudden Death (SD) in Subset Populations HuiKuri HV NEJM 2001 Sudden Death (SD) in Subset Populations SD in Competitive Athletes
More informationLeft ventricular outflow tract obstruction: indications and limitations of current therapies
Left ventricular outflow tract obstruction: indications and limitations of current therapies Costas O Mahony Inherited Cardiovascular Diseases Unit, The Heart Hospital, London, UK. None to declare Conflicts
More informationVentricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center
Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac
More informationCardiomyopathy: The Good, the Bad.and the Insurable?
Cardiomyopathy: The Good, the Bad.and the Insurable? WAHLU Spring Seminar 2014 Joy Geiger, RN, BSN, ALMI Medical Consultant The Northwestern Mutual Life Insurance Company Milwaukee, WI Objectives Overview
More informationHeart Rhythm Disorders. How do you quantify risk?
Heart Rhythm Disorders How do you quantify risk? Heart Rhythm Disorders Scale of the Problem 1/2 population will have an episode of transient loss of consciousness (T-LOC) at some stage in their life.
More information2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential
More informationUpdate on Evaluation and Nonsurgical Treatment Strategies for the Symptomatic Patient with HCM
Update on Evaluation and Nonsurgical Treatment Strategies for the Symptomatic Patient with HCM Richard G. Bach, MD, FACC, FAHA Professor of Medicine Director, Hypertrophic Cardiomyopathy Center Washington
More informationSudden Death in Athletes: What is the role of ECG Screening?
Sudden Death in Athletes: What is the role of ECG Screening? Byron K. Lee MD Professor of Medicine Director of EP Laboratory leeb@medicine.ucsf.edu Division of Cardiology Cardiac Electrophysiology Arrhythmias,
More informationEcho Evaluation of the Heart of an Athlete
Echo Evaluation of the Heart of an Athlete 18 th SA Heart Congress, 2017 Johannesburg, South Africa November 9-12, 2017 Naser Ammash. MD Professor of Medicine Practice Chair, Cardiovascular Department
More informationΕμφύτευση απινιδωτών για πρωτογενή πρόληψη σε ασθενείς που δεν περιλαμβάνονται στις κλινικές μελέτες
Εμφύτευση απινιδωτών για πρωτογενή πρόληψη σε ασθενείς που δεν περιλαμβάνονται στις κλινικές μελέτες Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος Dr. Konstantinou
More informationΜΥΟΚΑΡΔΙΟΠΑΘΕΙΕΣ. Ανεξήγητη βραδυκαρδία µε ή χωρίς διαταραχές κολποκοιλιακής αγωγής: τι µπορεί να κρύβει? ΕΦΗ Ι. ΠΡΑΠΠΑ Καρδιολόγος
ΜΥΟΚΑΡΔΙΟΠΑΘΕΙΕΣ Ανεξήγητη βραδυκαρδία µε ή χωρίς διαταραχές κολποκοιλιακής αγωγής: τι µπορεί να κρύβει? ΕΦΗ Ι. ΠΡΑΠΠΑ Καρδιολόγος Β Καρδιολογική Κλινική, ΠΓΝΑ «Ο ΕΥΑΓΓΕΛΙΣΜΟΣ» CONFLICT of INTEREST : none
More informationCardiac Conditions in Sport & Exercise. Cardiac Conditions in Sport. USA - Sudden Cardiac Death (SCD) Dr Anita Green. Sudden Cardiac Death
Cardiac Conditions in Sport & Exercise Dr Anita Green Cardiac Conditions in Sport Sudden Cardiac Death USA - Sudden Cardiac Death (SCD)
More informationRole of CMR in heart failure and cardiomyopathy
Role of CMR in heart failure and cardiomyopathy Hajime Sakuma Department of Radiology, Mie University Late gadolinium enhancement (LGE) LGE MRI can demonstrate site of necrosis, fibrosis or deposition
More informationWho does not need a primary preventive ICD?
Who does not need a primary preventive ICD? Hildegard Tanner, Bern Universitätsklinik für Kardiologie Disclosure of potential conflicts of interest Travel grants for educational purposes from: Biosense
More informationArthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY. DISCLOSURE INFORMATION Arthur J.
Saving Lives and Preventing Heart Failure: The MADIT Family of Trials Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY Update in Electrocardiography
More informationICD. Guidelines and Critical Review of Trials. Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011
ICD Guidelines and Critical Review of Trials Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011 Disclosure Relevant Financial Relationship(s) None Off
More informationHypertrophic Cardiomyopathy
019-CardioCase:019-CardioCase 4/16/07 1:39 PM Page 19 Hypertrophic Cardiomyopathy Abdullah Alshehri, MD; and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Presley s check-up Presley, 37, discovered
More informationRisk Factors for Sudden cardiac Death
Risk Factors for Sudden cardiac Death A. Arenal Arrhythmias in competitive sports Disclosure Conflict of interest Advisory board: Medtronic, Boston Scientific Research grants: Medtronic, Boston Scientific,
More informationPreventing Sudden Death Current & Future Role of ICD Therapy
Preventing Sudden Death Current & Future Role of ICD Therapy Derek V Exner, MD, MPH, FRCPC, FACC, FAHA, FHRS Professor, Libin Cardiovascular Institute of Alberta Canada Research Chair, Cardiovascular Clinical
More informationIn the Thick of It: Hypertrophic Cardiomyopathy
In the Thick of It: Hypertrophic Cardiomyopathy Munir S. Janmohamed M.D. FACC Assistant Clinical Professor of Medicine Director, Heart Failure Outreach Department of Medicine, Division of Cardiology Advanced
More informationSudden Cardiac Death in Sports: Causes and Current Screening Recommendations
Sports Cardiology Sudden Cardiac Death in Sports: Causes and Current Screening Recommendations Domenico Corrado, MD, PhD Inherited Arrhytmogenic Cardiomyopathy Unit Department of Cardiac, Thoracic and
More informationHYPERTENSION AND HEART FAILURE
HYPERTENSION AND HEART FAILURE Kenya Cardiac Society Symposium Feb 2017 Dr Jeilan Mohamed No conflict of interests . Geoffrey, 45 yr old hypertensive office worker male from Nairobi, has just watched his
More informationICD Therapy. Disclaimers
ICD Therapy Rodney Horton, MD Texas Cardiac Arrhythmia Institute Texas Cardiovascular, PA Austin, TX Speaker s Bureau St. Jude Medical Medtronic Boston Scientific Disclaimers Clinical Advisory Panel St.
More informationInterpretation and Consequences of Repolarisation Changes in Athletes
Interpretation and Consequences of Repolarisation Changes in Athletes Professor Sanjay Sharma E-mail sasharma@sgul.ac.uk @SSharmacardio Disclosures: None Athlete s ECG Vagotonia Sinus bradycardia Sinus
More informationAlcohol Septal Abla-on: Is This Now First Line Treatment for Hypertrophic Obstruc-ve Cardiomyopathy (HOCM)?
Alcohol Septal Abla-on: Is This Now First Line Treatment for Hypertrophic Obstruc-ve Cardiomyopathy (HOCM)? Sarang Mangalmur+, MD Bryn Mawr Hospital, PA NCVH New Jersey 2015 Disclosures No relevant disclosures
More informationHow NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto
How NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto Introduction Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy,
More informationCardiomyopathy. Jeff Grubbe MD FACP, Chief Medical Director, Allstate Life & Retirement
Cardiomyopathy Jeff Grubbe MD FACP, Chief Medical Director, Allstate Life & Retirement Nebraska Home Office Life Underwriters Association March 20, 2018 1 Cardiomyopathy A myocardial disorder in which
More informationSPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM
SPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM Rio De Janeiro 2016 Sport and Exercise Cardiology Symposium SBC/SOCERJ ACC Sharlene M. Day, MD Associate Professor, Cardiovascular Medicine Director,
More informationSudden Cardiac Death and Asians Disclosures
Sudden Cardiac Death and Asians Disclosures 7 February 2009 Asian Heart and Vascular Symposium None Zian H. Tseng, M.D., M.A.S. Assistant Professor of Medicine Cardiac Electrophysiology Section University
More informationMitral Valve Prolapse and Sudden Death. JF Avierinos Hôpital Timone Marseille January 27th, 2017
Mitral Valve Prolapse and Sudden Death JF Avierinos Hôpital Timone Marseille January 27th, 2017 Mitral Valve Prolapse Between Benign and Malignant the Long Story of Figure an Ongoing Controversy of a Pathologic
More informationThe Athlete s Heart. Role of Echo. Neil J. Weissman, MD MedStar Health Research Institute & Professor of Medicine Georgetown University
The Athlete s Heart Role of Echo Neil J. Weissman, MD MedStar Health Research Institute & Professor of Medicine Georgetown University Washington, D.C. Disclosures Grant support (to institution) for Core
More informationPrevention of Sudden Death in ARVC
ESC Munich, August 29, 2012 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC): Prevention of Sudden Death in ARVC Thomas Wichter, MD, FESC Professor of Medicine - Cardiology Marienhospital Osnabrück
More informationName of Presenter: Marwan Refaat, MD
NAAMA s 24 th International Medical Convention Medicine in the Next Decade: Challenges and Opportunities Beirut, Lebanon June 26 July 2, 2010 I have no actual or potential conflict of interest in relation
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationArrhythmias Focused Review. Who Needs An ICD?
Who Needs An ICD? Cesar Alberte, MD, Douglas P. Zipes, MD, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN Sudden cardiac arrest is one of the most common causes
More informationHypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy A Presentation for the MUD meeting January, 2018 Reviewed by Bill Rooney MD VP/Medical Director 1 https://commons.wikimedia.org/wiki/file:blausen_0166_cardiomyopathy_hypertrophic.p
More informationThe Hypertrophic Cardiomyopathy (HCM) Center
The Hypertrophic Cardiomyopathy (HCM) Center Comprehensive HCM management from a team you can trust An internationally recognized Center of Excellence in the diagnosis and treatment of HCM The most advanced
More informationRestrictive Cardiomyopathy
ESC Congress 2011, Paris Imaging Unusual Causes of Cardiomyopathy Restrictive Cardiomyopathy Kazuaki Tanabe, MD, PhD Professor of Medicine Chair, Division of Cardiology Izumo, Japan I Have No Disclosures
More informationAthlete s Heart vs. Cardiomyopathy
Athlete s Heart vs. Cardiomyopathy Linda D. Gillam, MD, MPH, FASE Chair, Department of Cardiovascular Medicine Medical Director, Cardiovascular Service Line Former Team Cardiologist to the New York Jets
More informationSynopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist
Synopsis of Management on Ventricular arrhythmias M. Soni MD Interventional Cardiologist No financial disclosure Premature Ventricular Contraction (PVC) Ventricular Bigeminy Ventricular Trigeminy Multifocal
More informationProfessor Sanjay Sharma St George s University of London
How to Evaluate an Athlete of Afro- Caribbean Origin. Professor Sanjay Sharma St George s University of London Background: Causes of SCD in Sport Young competitive athlete Personal and family history Physical
More informationA novel clinical risk prediction model for sudden cardiac death in HCM: a proof of concept study
A novel clinical risk prediction model for sudden cardiac death in HCM: a proof of concept study C O Mahony,* S Rahman,** E Biagini, C Rappezzi, L Monseratt, J Gimeno, G Limongeli, A Anastasakis, W McKenna,*
More informationEVALUATION OF THE ATHLETE. Karen Stout, MD Professor, Medicine and Pediatrics University of Washington
EVALUATION OF THE 12 ATHLETE Karen Stout, MD Professor, Medicine and Pediatrics University of Washington NO DISCLOSURES OUTLINE Why evaluate athletes? What s the problem? What evaluation should be done?
More informationLa valutazione dell atleta: è una strategia salva-vita e costo-efficace?
La valutazione dell atleta: è una strategia salva-vita e costo-efficace? Primo trattato di Medicina Wilson and Jungner s criteria In the 1960s the World Health Organization adopted the Wilson and Jungner
More informationHypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy Vincent L. Sorrell, MD Anthony N. DeMaria Professor of Medicine (Card/ Rad) University of Kentucky / Gill Heart Institute Assistant Chief, Division of Cardiovascular Medicine
More informationPrevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias
Prevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias The Toronto ACS Summit Toronto, March 1, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology
More informationmarked increase in thickness of walls of heart in patient with HCM.
Surgical Management of Hypertrophic Obstructive Cardiomyopathy Hani K. Najm MD, Msc, FRCSC, FRCS (Glasg Glasg), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi
More informationUsefulness of Delayed Enhancement by Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy as a Marker of Disease and Its Severity
Usefulness of Delayed Enhancement by Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy as a Marker of Disease and Its Severity G.D.Aquaro, MD Fondazione G.Monasterio Regione Toscana/CNR Pisa, Italy
More informationEchocardiographic Evaluation of the Cardiomyopathies. Stephanie Coulter, MD, FACC, FASE April, 2016
Echocardiographic Evaluation of the Cardiomyopathies Stephanie Coulter, MD, FACC, FASE April, 2016 Cardiomyopathies (CMP) primary disease intrinsic to cardiac muscle Dilated CMP Hypertrophic CMP Infiltrative
More informationSlide 1. Slide 2. Slide 3. Sudden Cardiac Death In Athletes. Epidemiology. Epidemiology. Shaun McMurtry, MD Primary Care Sports Medicine
Slide 1 Sudden Cardiac Death In Athletes Shaun McMurtry, MD Primary Care Sports Medicine Slide 2 Epidemiology College and Professional Athletes 500,000 participants each year Competitive Athletics Estimated
More informationThe Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia
The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia By Sandeep Joshi, MD and Jonathan S. Steinberg, MD Arrhythmia Service, Division of Cardiology
More informationPre-Participation Athletic Cardiac Screening
Pre-Participation Athletic Cardiac Screening Kimberly A Krabill, MD Pediatric and Fetal Cardiologist Northwest Congenital Heart Care, Division of MedNax Cardiology Update for Primary Care Symposium July
More informationDo All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationHypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy From Genetics to ECHO Alexandra A Frogoudaki Second Cardiology Department ATTIKON University Hospital Athens University Athens, Greece EUROECHO 2010, Copenhagen, 11/12/2010
More informationHCM in THE YOUNG Andre Keren MD Hadassah-Hebrew University Hospital, Jersualem, Israel
HCM in THE YOUNG Andre Keren MD Hadassah-Hebrew University Hospital, Jersualem, Israel Tel Aviv 5.6.09 Hypertrophic Cardiomyopathy Prevalence: Author n Method % Savage 1983 3000 M mode 0.3 Hada 1987 12841
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the
More informationRisk prediction in inherited conditions Laminopathies
Risk prediction in inherited conditions Laminopathies Karim Wahbi Cochin hospital, Paris karim.wahbi@aphp.fr Risk prediction in laminopathies Current approach for risk stratification A new score to predict
More informationRisk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
More informationWhen to implant an ICD in systemic right ventricle?
When to implant an ICD in systemic right ventricle? Département de rythmologie et de stimulation cardiaque Nicolas Combes n.combes@clinique-pasteur.com Pôle de cardiologie pédiatrique et congénitale Risk
More informationClinical Course of Hypertrophic Cardiomyopathy With Survival to Advanced Age
Journal of the American College of Cardiology Vol. 42, No. 5, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00855-6
More informationΠρόληψη του ΑΚΘ σε ασθενείς με μη-ισχαιμική μυοκαρδιοπάθεια:
Πρόληψη του ΑΚΘ σε ασθενείς με μη-ισχαιμική μυοκαρδιοπάθεια: Νεώτερα δεδομένα στη διαστρωμάτωση κινδύνου Εμμ. Μ. Κανουπάκης MD, PhD, FESC Πανεπιστημιακό Νοσοκομείο Ηρακλείου NIDCM Presence of LV dilatation
More informationSyncope in Heart Failure Patients How to judge and treat? Jean-Claude Deharo, MD, FESC Marseilles, France
Syncope in Heart Failure Patients How to judge and treat? Jean-Claude Deharo, MD, FESC Marseilles, France Syncope in advanced heart failure: high risk of sudden death N = 491 patients with HF (NYHA III-IV)
More informationSupplementary Online Content
Supplementary Online Content Tseng ZH, Hayward RM, Clark NM, et al. Sudden death in patients with cardiac implantable electronic devices. JAMA Intern Med. Published online June 22, 2015. doi:10.1001/jamainternmed.2015.2641.
More informationTakotsubo syndrome. Ευτυχία Σμπαρούνη, FACC, FESC
Takotsubo syndrome Ευτυχία Σμπαρούνη, FACC, FESC Definition Takotsubo Apical ballooning Broken heart syndrome Stress cardiomyopathy Cathecholaminergic cardiomyopathy Epidemiology 1990 first report by Japanese
More information